Skip to main content

Peer Review reports

From: Safety and efficacy of Empagliflozin in Pakistani Muslim patients with type 2 diabetes (SAFE-PAK); a randomized clinical trial

Original Submission
27 Jun 2022 Submitted Original manuscript
18 Jul 2022 Author responded Author comments - Azizul Hasan Aamir
22 Jul 2022 Author responded Author comments - Azizul Hasan Aamir
Resubmission - Version 2
18 Jul 2022 Submitted Manuscript version 2
25 Jul 2022 Author responded Author comments - Azizul Hasan Aamir
Resubmission - Version 3
25 Jul 2022 Submitted Manuscript version 3
31 Jul 2022 Reviewed Reviewer Report - Athanasia Papazafiropoulou
10 Aug 2022 Reviewed Reviewer Report
20 Aug 2022 Author responded Author comments - Azizul Hasan Aamir
Resubmission - Version 4
20 Aug 2022 Submitted Manuscript version 4
31 Aug 2022 Reviewed Reviewer Report - Athanasia Papazafiropoulou
1 Nov 2022 Reviewed Reviewer Report
6 Nov 2022 Author responded Author comments - Azizul Hasan Aamir
Resubmission - Version 5
6 Nov 2022 Submitted Manuscript version 5
Publishing
14 Nov 2022 Editorially accepted
28 Nov 2022 Article published 10.1186/s12902-022-01213-1

You can find further information about peer review here.

Back to article page